Atreca (BCEL) Stock Analysis

What Atreca does

Atreca, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing antibody-based immunotherapies for various solid tumor indications. Its lead investigational therapeutic, ATRC-101, is a monoclonal antibody distinguished by its novel mechanism of action and a unique target, both identified through the company's proprietary discovery platform. In in vitro studies, ATRC-101 has demonstrated reactivity with a significant proportion of human ovarian, non-small cell lung, colorectal, and breast cancer samples sourced from diverse patient populations. The pipeline also includes APN-122597, a receptor tyrosine kinase engineered to specifically target tumor tissues, and ATRC-501/MAM01, an agent aimed at the circumsporozoite protein of Plasmodium falciparum for malaria treatment. Beyond its internal programs, Atreca maintains strategic alliances, including a collaboration and licensing agreement with Xencor, Inc. for the research, development, and commercialization of innovative CD3 bispecific antibodies in oncology. Additionally, it holds a licensing agreement with the Bill & Melinda Gates Medical Research Institute for the advancement and commercialization of MAM01/ATRC-501, specifically for malaria prevention. Founded in 2010, Atreca, Inc. is headquartered in San Carlos, California.

Key metrics

ETFs linked to BCEL

Broad-market and Healthcare sector ETFs an investor holding Atreca is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how BCEL fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Atreca?

Atreca trades under the ticker BCEL on NASDAQ.

Which exchange is BCEL listed on?

BCEL is listed on NASDAQ.

What sector does Atreca operate in?

Atreca is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze BCEL in a portfolio?

PortView shows BCEL's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.